<DOC>
	<DOCNO>NCT01725802</DOCNO>
	<brief_summary>In Phase I/IIa study , effect continuous subcutaneous administration LD/CD solution ( ND0612 ) safety PK profile LD examine .</brief_summary>
	<brief_title>A Phase I/IIa Study Safety , Tolerability Plasma Concentration Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution ( ND0612 ) PD Patients</brief_title>
	<detailed_description>Design : single center , double-blind , randomize , placebo-controlled , crossover study . Study Drug : Subcutaneous ( SC ) , ND0612 ( LD/CD solution ) placebo ( saline ) administer via continuously via CRONO Five SC pump . A 1-week washout period apply treatment . Population : Eight ( 8 ) PD subject .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Main Men woman idiopathic Parkinson 's disease Subjects must experience motor fluctuation associate LD/CD dose Modified Hoehn Yahr stage &lt; 5 Subjects must take optimized stable levodopa/dopa decarboxylase inhibitor therapy Women must postmenopausal , surgically sterilize , use adequate birth control . Women childbearing potential must negative pregnancy test ( serum betaHCG ) screening . Subjects must age 30 old . Subjects must willing able give inform consent . Main Subjects clinically significant unstable medical surgical condition Subjects clinically significant psychiatric illness . Premenopausal woman , use birth control method . Subjects take experimental medication within 60 day prior baseline . Subject undergone neurosurgical intervention Parkinson 's disease ( e.g. , pallidotomy , thalamotomy , transplantation deep brain stimulation ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>